Search
ranibizumab ophthalmic (Lucentis, Byooviz)
Tradename: Lucentis (FDA approved 2006).
Aslo see more general term ranibizumab
Indications:
- macular degeneration
- diabetic macular edema [2,4]
Dosage:
- intavitreal injection of 0.3-0.5 mg monthly
Adverse effects:
- conjunctival hemorrhage
- eye pain
- floaters
- increased intra-ocular pressure [2]
- ophthalmitis
- retinal detachment [2]
Mechanism of action:
- angiogenesis inhibitor, binds to & inhibits VEGF
Notes:
- cost $2000/0.5 mg dose
- according to the Washington Post, this is the same drug as bevacizumab (Avastin) both produced by Genentech [3]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
ranibizumab (Lucentis, Byooviz)
ophthalmic agent (eyedrops)
References
- Rosenfeld PJ et al
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med 2006, 355:1419
PMID: 17021318
- Brown DM et al
Ranibizumab versus verteporfin for neovascular age-related
macular degeneration.
N Engl J Med 2006, 355:1432
PMID: 17021319
- Steinbrook R.
The price of sight - Ranibizumab, bevacizumab, and the
treatment of macular degeneration.
N Engl J Med 2006, 355:1409
PMID: 17021315
- Stone EM.
A very effective treatment for neovascular macular
degeneration
N Engl J Med 2006, 355:1493
PMID: 17021326
- FDA News Release: Aug. 10, 2012
FDA approves Lucentis to treat diabetic macular edema
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315130.htm
- Kliff S
This $2,000 drug says everything about our messed up health-
care system.
Washington Post Dec 9, 2013
http://www.washingtonpost.com/blogs/wonkblog/wp/2013/12/09/this-2000-drug-says-everything-about-our-messed-up-health-care-system/
- The Diabetic Retinopathy Clinical Research Network.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema.
N Engl J Med. 2015 Feb 18.
PMID: 25692915
http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
- Martin DF, Maguire MG.
Treatment Choice for Diabetic Macular Edema.
N Engl J Med. 2015 Feb 18. [Epub ahead of print]
PMID: 25692914
http://www.nejm.org/doi/full/10.1056/NEJMe1500351